Psychotic symptoms in Parkinson's disease: Pathophysiology and management

Expert Opinion on Drug Safety

Volumn 3, Issue 3, 2004, Pages 209-220

  Bosboom, J L W ^a   Wolters, ECh ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical antipsychotics; Cholinesterase inhibitors; Delusions; Haluccinations; Parkinson's disease

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE; GALANTAMINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE;

AGRANULOCYTOSIS; ANOREXIA; BRADYKINESIA; CAREGIVER; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CORPUS STRIATUM; DEGENERATIVE DISEASE; DELUSION; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DISTRESS SYNDROME; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG INDUCED DISEASE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; HYPOKINESIA; HYPOTENSION; LEUKOPENIA; LIVER TOXICITY; MOTOR DYSFUNCTION; MUSCLE STIFFNESS; MYOCARDITIS; NAUSEA; NERVE CELL DEGENERATION; NEUROLEPTIC HYPERSENSITIVITY; NURSING HOME; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; RIGIDITY; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; TACHYCARDIA; THROMBOCYTOPENIA; TREMOR; VISUAL HALLUCINATION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 2942689404     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.3.209     Document Type: Review

References (149)

1. JELLINGER KA: Neuropathological correlates of mental dysfunction in Parkinson's disease: an update. In: Mental dysfunction in Parkinson's disease II. Wolters ECh (Ed.), Academic Pharmaceutical Productions, Utrecht, The Netherlands (1999):82-105.
2. KARLSEN KH, LARSEN JP, TANDBERG E, MALAND JG: Quality of life measurements in patients with Parkinson's disease: a community-based study. Eur. J. Neurol. (1998) 5(5):443-450.
3. AARSLAND D, LARSEN JP, KARLSEN K, LIM NG, TANDBERG E: Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int. J. Geriatr. Psychiatry (1999) 14(10):866-874.
4. AARSLAND D, LARSEN JP, TANDBERG E, LAAKE K: Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J. Am. Geriatr Soc. (2000) 48(8):938-942.
5. GOETZ CG, STEBBINS GT: Risk factors for nursing home placement in advanced Parkinson's disease. Neurology (1993) 43(11):2227-2229.
6. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (1994).
7. POEWE W: Psychosis in Parkinson's disease. Mov. Disord. (2003) 18(Suppl. 6):S80-S87.
8. GRAHAM JM, GRUNEWALD RA, SAGAR HJ: Hallucinosis in idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1997) 63(4):434-440.
9. FENELON G, MAHIEUX F, HUON R, ZIEGLER M: Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain (2000) 123(Pt 4):733-745.
10. GOETZ CG, LEURGANS S, PAPPERT EJ, RAMAN R, STEMER AB: Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology (2001) 57(11):2078-2082.
11. AARSLAND D, BALLARD C, LARSEN JP, MCKEITH I: A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int. J. Geriatr. Psychiatry (2001) 16(5):528-536.
12. WOLTERS EC: Psychiatric complications in the treatment of Parkinson's disease. Adv. Neurol. (2001) 86:385-393.
13. WOLTERS EC, FRANCOT CM: Mental dysfunctions in Parkinson's disease. Parkinsonism Relat. Disord. (1998) 4:107-112.
14. RONDOT P, DE RECONDO J, COIGNET A, ZIEGLER M: Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv. Neurol. (1984) 40:259-269.
15. GOETZ CG, PAPPERT EJ, BLASUCCI LM et al.: Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology (1998) 50(2):515-517.
16. SANCHEZ-RAMOS JR, ORTOLL R, PAULSON GW: Visual hallucinations associated with Parkinson's disease. Arch. Neurol. (1996) 53(12):1265-1268.
17. AARSLAND D, LARSEN JP, CUMMINS JL, LAAKE K: Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: a community-based study. Arch. Neurol. (1999) 56(5):595-601.
18. GOETZ CG, VOGEL C, TANNER CM, STEBBINS GT: Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology (1998) 51(3):811-814.
19. DE SMET Y, RUBERG M, SERDARU M, DUBOIS B, LHERMITTE F, AGID Y: Confusion, dementia and anticholinergics in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1982) 45 (12):1161-1164.
20. SAINT-CYR JA, TAYLOR AE, LANG AE: Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology (1993) 43(12 Suppl. 6):S47-S52.
21. MCKEITH IG, GALASKO D, KOSAKA K et al.: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 47(5):1113-1124.
22. RICHARD IH, PAPKA M, RUBIO A, KURLAN R. Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov. Disord. (2002) 17(6):1161-1165.
23. DUBOIS B, PILLON B: Cognitive deficits in Parkinson's disease. J. Neurol. (1997) 244(1):2-8.
24. CONNOR DJ, SALMON DP, SANDY TJ, GALASKO D, HANSEN LA, THAL LJ: Cognitive profiles of autopsy-confirmed Lewy body variant versus pure Alzheimer's disease. Arch. Neurol. (1998) 55(7):994-1000.
25. BALLARD CG, AARSLAND D, MCKEITH I et al.: Fluctuations in attention: PD dementia versus DLB with parkinsonism. Neurology (2002) 59(11):1714-1720.
26. HARDING AJ, HALLIDAY GM: Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. (Berl.) (2001) 102(4):355-363.
27. MCKEITH IG: Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol. Clin. (2000) 18(4):865-902.
28. BURN DJ, MCKEITH IG: Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov. Disord. (2003) 18(Suppl. 6):S72-S79.
29. ZARRANZ JJ, ALEGRE J, GOMEZ-ESTEBAN JC et al.: The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia. Ann. Neurol. (2004) 55(2):164-173.
30. LITVAN I, MACINTYRE A, GOETZ CG et al.: Accuracy of the clinical diagnoses of Lewy body disease, Parkinson's disease, and dementia with Lewy bodies: a clinicopathologic study. Arch. Neurol. (1998) 55(7):969-978.
31. HOLROYD S, CURRIE L, WOOTEN GF: Prospective study of hallucinations and delusions in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (2001) 70(6):734-738.
32. KLEIN C, KOMPF D, PULKOWSKI U, MOSER A, VIEREGGE P: A study of visual hallucinations in patients with Parkinson's disease. J. Neurol. (1997) 244(6):371-377.
33. GRAHAM JM, SUSSMAN JD, FORD KS, SAGAR HJ: Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J. Neurol. Neurosurg. Psychiatry (1998) 65(5):774-777.
34. INZELBERG R, KIPERVASSER S, KORCZYN AD: Auditory hallucinations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1998) 64(4):533-535.
35. BARNES J, DAVID AS: Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J. Neurol. Neurosurg. Psychiatry (2001) 70(6):727-733.
36. BASSIONY MM, LYKETSOS CG: Delusions and hallucinations in Alzheimer's disease: review of the brain decade. Psychosomatics (2003) 44(5):388-401.
37. ALEXANDER GE, DELONG MR, STRICK PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. (1986) 9:357-381.
38. UHL GR, HEDREEN JC, PRICE DL: Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology (1985) 35(8):1215-1218.
39. RINNE JO, RUMMUKAINEN J, PALJARVI L, RINNE UK: Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann. Neurol. (1989) 26(1):47-50.
40. PAULUS W, JELLINGER K: The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. (1991) 50(6):743-755.
41. SCATTON B, ROUQUIER L, JAVOYAGID F, AGID Y: Dopamine deficiency in the cerebral-cortex in Parkinson's disease. Neurology (1982) 32(9):1039-1040.
42. JAVOY-AGID F, AGID Y: Is the mesocortical dopaminergic system involved in Parkinson's disease? Neurology (1980) 30(12):1326-1330.
43. NIEOULLON A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. (2002) 67(1):53-83.
44. MATTAY VS, TESSITORE A, CALLICOTT JH et al.: Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann. Neurol. (2002) 51(2):156-164.
45. STAM CJ, VISSER SL, OP DE COUL AA et al.: Disturbed frontal regulation of attention in Parkinson's disease. Brain (1993) 116(Pt 5):1139-1158.
46. DAVIES P, MALONEY AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (1976) 2(8000):1403.
47. WHITEHOUSE PJ, HEDREEN JC, WHITE CL III, PRICE DL: Basal forebrain neurons in the dementia of Parkinson's disease. Ann. Neurol. (1983) 13(3):243-248.
48. PERRY EK, CURTIS M, DICK DJ et al.: Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry (1985) 48(5):413-421.
49. TIRABOSCHI P, HANSEN LA, ALFORD M et al.: Cholinergic dysfunction in diseases with Lewy bodies. Neurology (2000) 54(2):407-411.
50. BALLARD C, PIGGOTT M, JOHNSON M et al.: Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann. Neurol. (2000) 48(6):868-876.
51. PERRY EK, MCKEITH I, THOMPSON P et al.: Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann. NY Acad. Sci. (1991) 640:197-202.
52. MATTILA PM, ROYTTA M, LONNBERG P, MARJAMAKI P, HELENIUS H, RINNE JO: Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol. (Berl.) (2001) 102(2):160-166.
53. MESULAM MM, MUFSON EJ, LEVEY AI, WAINER BH: Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. (1983) 214(2):170-197.
54. MESULAM MM, MUFSON EJ, WAINER BH, LEVEY AI: Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1 - Ch6). Neuroscience (1983) 10(4):1185-1201.
55. PERRY EK, JOHNSON M, KERWIN JM et al.: Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol. Aging (1992) 13(3):393-400.
56. KUHL DE, MINOSHIMA S, FESSLER JA et al.: In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol. (1996) 40(3):399-410.
57. PERRY E, WALKER M, GRACE J, PERRY R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. (1999) 22(6):273-280.
58. EVERITT BJ, ROBBINS TW: Central cholinergic systems and cognition. Annu. Rev. Psychol. (1997) 48:649-684.
59. SARTER M, BRUNO JP: Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends Neurosci. (1999) 22(2):67-74.
60. SARTER M, BRUNO JP: Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res. Brain Res. Rev. (1997) 23(1-2):28-46.
61. VOYTKO ML: Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Behav. Brain Res. (1996) 75(1-2):13-25.
62. SHIMOMURA T, MORI E, YAMASHITA H et al.: Cognitive loss in dementia with Lewy bodies and Alzheimer's disease. Arch. Neurol. (1998) 55(12):1547-1552.
63. HIRSCH EC, GRAYBIEL AM, DUYCKAERTS C, JAVOY-AGID F: Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson's disease and in progressive supranuclear palsy. Proc. Natl. Acad. Sci. USA (1987) 84(16):5976-5980.
64. JELLINGER K: The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry (1988) 51(4):540-543.
65. ZWEIG RM, JANKEL WR, HEDREEN JC, MAYEUX R, PRICE DL: The pedunculopontine nucleus in Parkinson's disease. Ann. Neurol. (1989) 26(1):41-46.
66. ASKENASY JJ: Sleep in Parkinson's disease. Acta Neurol. Scand. (1993) 87(3):167-170.
67. KOSTIC VS, SUSIC V, COVICKOVIC-STERNIC N, MARINKOVIC Z, JANKOVIC S: Reduced rapid eye movement sleep latency in patients with Parkinson's disease. J. Neurol. (1989) 236(7):421-423.
68. COMELLA CL, TANNER CM, RISTANOVIC RK: Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann. Neurol. (1993) 34(5):710-714.
69. PAPPERT EJ, GOETZ CG, NIEDERMAN FG, RAMAN R, LEURGANS S: Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov. Disord. (1999) 14(1):117-121.
70. NAUSIEDA PA, WEINER WJ, KAPLAN LR, WEBER S, KLAWANS HL: Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin. Neuropharmacol. (1982) 5(2):183-194.
71. ARNULF I, BONNET AM, DAMIER P et al.: Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 55(2):281-288.
72. PERRY EK, PERRY RH: Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. (1995) 28(3):240-258.
73. MATTILA PM, RINNE JO, HELENIUS H, DICKSON DW. ROYTTA M: α-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. (Berl.) (2000) 100(3):285-290.
74. APAYDIN H, AHLSKOG JE, PARISI JE, BOEVE BF, DICKSON DW: Parkinson's disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. neurol. (2002) 59(1):102-112.
75. HURTIG HI, TROJANOWSKI JQ, GALVIN J. et al.: α-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 54(10):1916-1921.
76. HARDING AJ, BROE GA, HALLIDAY GM: Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain (2002) 125(Pt 2):391-403.
77. DE VOS RA, JANSEN EN, STAM FC, RAVID R, SWAAB DF: 'Lewy body disease': clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin. Neurol. Neurosurg. (1995) 97(1):13-22.
78. GOMEZ-TORTOSA E, NEWELL K, IRIZARRY MC, ALBERT M, GROWDON JH, HYMAN BT: Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology (1999) 53(6):1284-1291.
79. SANTACRUZ K, PAHWA R, LYONS K et al.: Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson's disease patients with and without dementia. Neurology (1999) 52(6):A476-A477.
80. MOSKOVITZ C, MOSES H III, KLAWANS HL: Levodopa-induced psychosis: a kindling phenomenon. Am. J. Psychiatry (1978) 135(6):669-675.
81. KLAWANS HL, GOETZ C, NAUSIEDA PA, WEINER WJ: Levodopa-induced dopamine receptor hypersensitivity. Trans. Am. Neurol. Assoc. (1977) 102:80-83.
82. RINNE UK, BRACCO F, CHOUZA C et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs (1998) 55(Suppl. 1):23-30.
83. PARKINSON STUDY GROUP: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAAM (2000) 284(15):1931-1938.
84. BIRKMAYER W, DANIELCZYK W, NEUMAYER E, RIEDERER P: Dopaminergic supersensitivity in parkinsonism. Adv. Neurol. (1975) 9:121-129.
85. 3 receptor antagonist. Neurology (1995) 45(7):1305-1308.
86. MELAMED E, ZOLDAN J, FRIEDBERG G, ZIV I, WEIZMANN A: Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv. Neurol. (1996) 69:545-550.
87. LAUTERBACH EC: Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia. Clin. Neuropharmacol. (1991) 14(6):547-555.
88. HAASE HJ, JANSSEN PAJ: The action of neuroleptic drugs: a psychiatric neurologic and pharmacological investigation. Year Book Medical Publ., Chicago, USA (1965).
89. KAPUR S, SEEMAN P: Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry (2001) 158(3):360-369.
90. SEEMAN P: Reply: atypical antipsychotics: mechanisms of action. Can. J. Psychiatry (2003) 48(1):62-64.
91. 2 pKi values. J. Pharmacol. Exp. Ther. (1989) 251(1 ):238-246.
92. MELTZER HY, LI Z, KANEDA Y, ICHIKAWA J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27(7):1159-1172.
93. SEEMAN P: Atypical antipsychotics: mechanism of action. Can. J. Psychiatry (2002) 47(1):27-38.
94. MCKEITH I, FAIRBAIRN A, PERRY R, THOMPSON P, PERRY E: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br. Med. J. (1992) 305(6855):673-678.
95. BALLARD C, GRACE J, MCKEITH I, HOLMES C: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet (1998) 351(9108):1032-1033.
96. FRIEDMAN JH, WAGNER RL: Symptoms of neuroleptic malignant syndrome. Am. J. Psychiatry (1987) 144(8):1105-1106.
97. PIGGOTT MA, PERRY EK, MCKEITH IG, MARSHALL E, PERRY RH: Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity. Lancet (1994) 343(8904):1044-1045.
98. PHILIBERT RA, ADAM LA, FRANK FM, CARNEY-DOEBBELING C: Olanzapine usage associated with neuroleptic malignant syndrome. Psychosomatics (2001) 42(6):528-529.
99. TORU M, MATSUDA O, MAKIGUCHI K, SUGANO K: Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J. Nerv. Ment. Dis. (1981) 169(5):324-327.
100. KEYSER DL, RODNITZKY RL: Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch. Intern. Med. (1991) 151(4):794-796.
101. FIGA-TALAMANCA L, GUALANDI C, DI MEO L, DI BATTISTA G, NERI G, LO RF: Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology (1985) 35(2):258-261.
102. NO AUTHORS LISTED: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. (1999) 340(10):757-763.
103. NO AUTHORS LISTED: Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet (1999) 353(9169):2041-2042.
104. ALVIR JM, LIEBERMAN JA, SAFFERMAN AZ, SCHWIMMER JL, SCHAAF JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. (1993) 329(3):162-167.
105. RUDOLF J, GROND M, NEVELING M, HEISS WD: Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J. Neural. Transm. (1997) 104(11-12):1305-1311.
106. KLEIN C, GORDON J, POLLAK L, RABEY JM: Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin. Neuropharmacol. (2003) 26(1):8-11.
107. BALDESSARINI RJ, FRANKENBURG FR: Clozapine. A novel antipsychotic agent. N. Engl. J. Med. (1991) 324(11):746-754.
108. SALLER CF, SALAMA AI: Seroquel: biochemical profile of a potential atypical antipsychotic. Pyschopharmacology (Berl.) (1993) 112(2-3):285-292.
109. MENZA MM, PALERMO B, MARK M: Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann. Clin. Psychiatry (1999) 11(3):141-144.
110. WEINER WJ, MINAGAR A, SHULMAN LM: Quetiapine for l-dopa-induced psychosis in PD. Neurology (2000) 54(7):1538.
111. DEWEY RB Jr, O'SUILLEABHAIN PE: Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology (2000) 55(11):1753-1754.
112. TARGUM SD, ABBOTT JL: Efficacy of quetiapine in Parkinson's patients with psychosis. J. Clin. Psychopharmacol. (2000) 20(1):54-60.
113. FERNANDEZ HH, TRIESCHMANN ME, BURKE MA, JACQUES C, FRIEDMAN JH: Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov. Disord. (2003) 18(5):510-514.
114. JUNCOS JL, EVATT ML, JEWART D: Long-term effects of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology (1998) 50(4):A70-A71.
115. JUNCOS JL, ARVANITIS L, SWEITZER D, YEUNG P, JEWART RD, NEMEROFF C: Quetiapine improves psychotic symptoms associated with Parkinson's disease. Neurology (1999) 52(6):A262.
116. FERNANDEZ HH, FRIEDMAN JH, JACQUES C, ROSENFELD M: Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. (1999) 14(3):484-487.
117. FERNANDEZ HH, LANNON MC, FRIEDMAN JH, ABBOTT BP: Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. (2000) 15(3):579-581.
118. WOLTERS EC, JANSEN EN, TUYNMAN-QUA HG, BERGMANS PL: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology (1996) 47(4):1085-1087.
119. FRIEDMAN J: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology (1998) 50(4):1195-1196.
120. MOLHO ES, FACTOR SA: Worsening of motor features of parkinsonism with olanzapine. Mov. Disord. (1999) 14(6):1014-1016.
121. ONDO WG, LEVY JK, VUONG KD, HUNTER C, JANKOVIC J: Olanzapine treatment for dopaminergic-induced hallucinations. Mov. Disord. (2002) 17(5):1031-1035.
122. BREIER A, SUTTON VK, FELDMAN PD, et al.: Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol. Psychiatry (2002) 52(5):438-445.
123. KNABLE MB, HEINZ A, RAEDLER T, WEINBERGER DR: Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res. (1997) 75(2):91-101.
124. LEOPOLD NA: Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov. Disord. (2000) 15(2):301-304.
125. MOHR E, MENDIS T, HILDEBRAND K, DE DEYN PP: Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov. Disord. (2000) 15(6):1230-1237.
126. WORKMAN RH Jr, ORENGO CA, BAKEY AA, MOLINARI VA, KUNIK ME: The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. (1997) 9(4):594-597.
127. ELLIS T, CUDKOWICZ ME, SEXTON PM, GROWDON JH: Clozapine and risperidone treatment of psychosis in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. (2000) 12(3):364-369.
128. RICH SS, FRIEDMAN JH, OTT BR: Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J. Clin. Psychiatry (1995) 56(12):556-559.
129. FORD B, LYNCH T, GREENE P: Risperidone in Parkinson's disease. Lancet (1994) 344(8923):681.
130. ALLEN RL, WALKER Z, D'ATH PJ, KATONA CL: Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet (1995) 346(8968):185.
131. MCKEITH IG, BALLARD CG, HARRISON RW: Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet (1995) 346(8976):699.
132. CUMMINGS JL, CYRUS PA, BIEBER F, MAS J, ORAZEM J, GULANSKI B: Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology (1998) 50(5):1214-1221.
133. ROGERS SL, FARLOW MR, DOODY RS, MOHS R, FRIEDHOFF LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology (1998) 50(1):136-145.
134. TARIOT PN, SOLOMON PR, MORRIS JC, KERSHAW P, LILIENFELD S, DING C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology (2000) 54(12):2269-2276.
135. GABELLI C: Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr. Med. Res. Opin. (2003) 19(2):69-82.
136. PERRY EK, IRVING D, KERWIN JM et al.: Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer's disease. Alzheimer Dis. Assoc. Disord. (1993) 7(2):69-79.
137. AARSLAND D, BRONNICK K, KARLSEN K: Donepezil for dementia with Lewy bodies: a case study. Int. J. Geriatr. Psychiatry (1999) 14(1):69-72.
138. FERGUSSON E, HOWARD R: Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int. J. Geriatr. Psychiatry (2000) 15(3):280-281.
139. SHEA C, MACKNIGHT C, ROCKWOOD K: Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int. Psychogeriatr. (1998) 10(3):229-238.
140. BERGMAN J, LERNER V: Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin. Neuropharmacol. (2002) 25(2):107-110.
141. FABBRINI G, BARBANTI P, AURILIA C, PAULETTI C, LENZI GL, MECO G: Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol. Sci. (2002) 23(1):41-43.
142. KAUFER DI, CATT KE, LOPEZ OL, DEKOSKY ST. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology (1998) 51(5):1512.
143. MCKEITH IG, GRACE JB, WALKER Z et al.: Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int. J. Geriatr. Psychiatry (2000) 15(5):387-392.
144. GRACE J, DANIEL S, STEVENS T et al.: Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int. Pychogeriatr. (2001) 13(2):199-205.
145. MCKEITH I, DEL SER T, SPANO P et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet (2000) 356(9247):2031-2036.
146. READING PJ, LUCE AK, MCKEITH IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment. preliminary findings from an open trial. Mov. Disord. (2001) 16(6):1171-1174.
147. BULLOCK R, CAMERON A: Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr. Med. Res. Opin. (2002) 18(5):258-264.
148. AARSLAND D, HUTCHINSON M, LARSEN JP: Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int. J. Geriatr. Psychiatry (2003) 18(10):937-941.
149. HUTCHINSON M, FAZZINI E: Cholinesterase inhibition in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry (1996) 61(3):324-325.